Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Nov 11;2013(11):CD010567.
doi: 10.1002/14651858.CD010567.pub2.

Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews

Philip J Wiffen  1 , Sheena Derry, R Andrew Moore, Dominic Aldington, Peter Cole, Andrew S C Rice, Michael P T Lunn, Katri Hamunen, Maija Haanpaa, Eija A Kalso
Affiliations
Meta-Analysis

Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews

Philip J Wiffen et al. Cochrane Database Syst Rev. .

Abstract

Background: Antiepileptic drugs have been used for treating different types of neuropathic pain, and sometimes fibromyalgia. Our understanding of quality standards in chronic pain trials has improved to include new sources of potential bias. Individual Cochrane reviews using these new standards have assessed individual antiepileptic drugs. An early review from this group, originally published in 1998, was titled 'Anticonvulsants for acute and chronic pain'. This overview now covers the neuropathic pain aspect of that original review, which was withdrawn in 2009.

Objectives: To provide an overview of the relative analgesic efficacy of antiepileptic drugs that have been compared with placebo in neuropathic pain and fibromyalgia, and to report on adverse events associated with their use.

Methods: We included reviews published in theCochrane Database of Systematic Reviews up to August 2013 (Issue 7). We extracted information from each review on measures of efficacy and harm, and methodological details concerning the number of participants, the duration of studies, and the imputation methods used, in order to judge potential biases in available data.We analysed efficacy data for each painful condition in three tiers, according to outcome and freedom from known sources of bias. The first tier met current best standards - at least 50% pain intensity reduction over baseline (or its equivalent), without the use of last observation carried forward (LOCF) for dropouts, an intention-to-treat (ITT) analysis, in parallel group studies with at least 200 participants lasting eight weeks or more. The second tier used data from at least 200 participants where one or more of the above conditions were not met. The third tier of evidence related to data from fewer than 200 participants, or with several important methodological problems that limited interpretation.

Main results: No studies reported top tier results.For gabapentin and pregabalin only we found reasonably good second tier evidence for efficacy in painful diabetic neuropathy and postherpetic neuralgia. In addition, for pregabalin, we found evidence of efficacy in central neuropathic pain and fibromyalgia. Point estimates of numbers needed to treat for an additional beneficial effect (NNTs) were in the range of 4 to 10 for the important outcome of pain intensity reduction over baseline of 50% or more.For other antiepileptic drugs there was no evidence (clonazepam, phenytoin), so little evidence that no sensible judgement could be made about efficacy (valproic acid), low quality evidence likely to be subject to a number of biases overestimating efficacy (carbamazepine), or reasonable quality evidence indicating little or no effect (lamotrigine, oxcarbazepine, topiramate). Lacosamide recorded such a trivial statistical superiority over placebo that it was unreliable to conclude that it had any efficacy where there was possible substantial bias.Any benefits of treatment came with a high risk of adverse events and withdrawal because of adverse events, but serious adverse events were not significantly raised, except with oxcarbazepine.

Authors' conclusions: Clinical trial evidence supported the use of only gabapentin and pregabalin in some neuropathic pain conditions (painful diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain) and fibromyalgia. Only a minority of people achieved acceptably good pain relief with either drug, but it is known that quality of life and function improved markedly with the outcome of at least 50% pain intensity reduction. For other antiepileptic drugs there was no evidence, insufficient evidence, or evidence of a lack of effect; this included carbamazepine. Evidence from clinical practice and experience is that some patients can achieve good results with antiepileptics other than gabapentin or pregabalin.There is no firm evidence to answer the important pragmatic questions about which patients should have which drug, and in which order the drugs should be used. There is a clinical effectiveness research agenda to provide evidence about strategies rather than interventions, to produce the overall best results in a population, in the shortest time, and at the lowest cost to healthcare providers.

PubMed Disclaimer

Conflict of interest statement

SD, RAM, AR, and PW have received research support from charities, government, and industry sources at various times. RAM, DA, EK, and PW have consulted for various pharmaceutical companies. RAM, DA, KH, EK and PC have received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. AR has provided consultancy advice through Imperial College Consultants for a number of companies engaged in neuropathic pain drug development. He receives research funding from Pfizer and Astellas and owns share options in Spinifex Pharmaceuticals. ML has no interests to declare.

Figures

1
1
Withdrawals due to adverse events or lack of efficacy according to daily dose of pregabalin
See this image and copyright information in PMC

Comment in

References

References to included reviews

Birse 2012
    1. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2] - DOI - PMC - PubMed
Corrigan 2012
    1. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2] - DOI - PMC - PubMed
Gill 2011
    1. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2] - DOI - PMC - PubMed
Hearn 2012
    1. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009318.pub2] - DOI - PMC - PubMed
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2011
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] - DOI - PMC - PubMed
Wiffen 2011a
    1. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD005451.pub2] - DOI - PMC - PubMed
Wiffen 2011b
    1. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006044.pub3] - DOI - PMC - PubMed
Wiffen 2013
    1. Wiffen PJ, Derry S, Lunn MPT, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD008314.pub3] - DOI - PMC - PubMed
Zhou 2013
    1. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD007963.pub2] - DOI - PubMed

Additional references

Attal 2010
    1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113‐e88. [DOI: 10.1111/j.1468-1331.2010.02999.x] - DOI - PubMed
AUREF 2012
    1. PaPaS author and referee guidance. http://papas.cochrane.org/papas‐documents (Accessed 23 May 2013).
Barres 2009
    1. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor alpha2delta‐1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139(2):380‐92. [DOI: 10.1016/j.cell.2009.09.025] - DOI - PMC - PubMed
Beydoun 2009
    1. Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial‐onset seizures. Expert Review of Neurotherapeutics 2009;9(1):33‐42. [DOI: 10.1586/14737175.9.1.3] - DOI - PubMed
Blom 1962
    1. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G.32883). Lancet 1962;1:839‐40. - PubMed
Bohlega 2010
    1. Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region. Journal of International Medical Research 2010;38(2):295‐317. [DOI: 10.1177/147323001003800201] - DOI - PubMed
Bouhassira 2008
    1. Bouhassira D, Lantéri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] - DOI - PubMed
Chaparro 2012
    1. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD008943.pub2] - DOI - PMC - PubMed
Chetty 2012
    1. Chetty S, Baalbergen E, Bhigjee AI, Kamerman P, Ouma J, Raath R, et al. Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa. South African Medical Journal 2012;102(5):312‐25. - PubMed
Chong 2000
    1. Chong MS, Smith TE. Anticonvulsants for the management of pain. Pain Reviews 2000;7:129‐49.
Chong 2003
    1. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clinical Journal of Pain 2003;19(1):59‐68. - PubMed
Chung 2010
    1. Chung WH, Hung SI, Chen YT. Genetic predisposition of life‐threatening antiepileptic‐induced skin reactions. Expert Opinion on Drug Safety 2010;9:15‐21. [DOI: 10.1517/14740330903427969] - DOI - PubMed
Clauw 2013
    1. Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long‐term treatment in fibromyalgia: a randomized trial. Arthritis Research and Therapy 2013;15(4):R88. - PMC - PubMed
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Dickenson 2007
    1. Dickenson AH, Ghandehari J. Anti‐convulsants and anti‐depressants. Handbook of Experimenta Pharmacology 2007;177:145‐77. - PubMed
Dworkin 2007
    1. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence‐based recommendations. Pain 2007;132(3132):237‐51. [DOI: 10.1016/j.pain.2007.08.033] - DOI - PubMed
Dworkin 2012
    1. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence‐based recommendations?. Pain 2012;153(4):869‐75. [DOI: 10.1016/j.pain.2012.01.015] - DOI - PubMed
Errington 2008
    1. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage‐gated sodium channels. Molecular Pharmacology 2008;73(1):157‐69. [DOI: 10.1124/mol.107.039867] - DOI - PubMed
Finnerup 2005
    1. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118(3):289‐305. [DOI: 10.1016/j.pain.2005.08.013] - DOI - PubMed
Glenny 2005
    1. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technology Assessment 2005;9(26):1‐134, iii‐iv. - PubMed
Grahame‐Smith 1992
    1. Grahame‐Smith DG, Aronson JK. Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford Textbook of Clinical Pharmacology and Drug Therapy. 2nd Edition. Oxford: Oxford University Press, 1992.
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. [DOI: 10.1111/j.1399-6576.2007.01486.x] - DOI - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26] - DOI - PMC - PubMed
Hall 2013
    1. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman 2010
    1. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] - DOI - PubMed
Holmes 2001
    1. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. New England Journal of Medicine 2001;344(15):1132‐8. [DOI: 10.1056/NEJM200104123441504] - DOI - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204‐5. [DOI: 10.1016/j.pain.2011.06.017] - DOI - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology 1991;10:276‐81. - PubMed
Khaliq 2007
    1. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2] - DOI - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] - DOI - PubMed
Koroschetz 2011
    1. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55] - DOI - PMC - PubMed
Lunn 2009
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2] - DOI - PubMed
McCleane 2000
    1. McCleane GJ. Lamotrigine in the management of neuropathic pain. The Clinical Journal of Pain 2000;16:321‐6. - PubMed
McNally 2006
    1. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self‐reported fibromyalgia in Canada. Chronic Diseases in Canada 2006;27(1):9‐16. - PubMed
McQuay 1995
    1. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311:1047‐52. - PMC - PubMed
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978‐1‐84619‐063‐6]
McQuay 2008
    1. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008;135(3):217‐20. [DOI: 10.1016/j.pain.2008.01.014] - DOI - PubMed
Moisset 2007
    1. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80‐8. - PubMed
Monks 1994
    1. Monks R. Psychotropic drugs. In: Wall PD, Melzack R editor(s). Textbook of Pain. 3rd Edition. Edinburgh: Churchill Livingstone, 1994:963‐89. [ISBN: 044304757X]
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐23. [ISBN: 978‐0‐931092‐69‐5]
Moore 2010a
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2010b
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain – establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010c
    1. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] - DOI - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2013a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The Costs and Consequences of Adequately Managed Chronic Non‐Cancer Pain and Chronic Neuropathic Pain. Pain Practice 2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2013b
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2013c
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: ] - PubMed
Moore 2013d
    1. Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. British Journal of Anaesthesia 2013;111(1):38‐45. [DOI: 10.1093/bja/aet126] - DOI - PubMed
Moore 2013e
    1. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain 2013;epub. [DOI: 10.1002/j.1532-2149.2013.00341.x] - DOI - PMC - PubMed
Moulin 2007
    1. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain ‐ consensus statement and guidelines from the Canadian Pain Society. Pain Research and Management 2007;12(1):13‐21. - PMC - PubMed
NICE 2013
    1. Draft Guidance. National Institute for Health and Clinical Excellence (2013) Neuropathic pain – pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings. National Institute for Health and Care Excellence Accessed August 2013. [www.nice.org.uk/nicemedia/live/13566/64189/64189.pdf ]
Nüesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
O'Connor 2009
    1. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122((10 Suppl)):S22‐32. [DOI: 10.1016/j.amjmed.2009.04.007] - DOI - PubMed
Oaklander 2013
    1. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154(11):2310‐6. [DOI: 10.1016/j.pain.2013.06.001] - DOI - PMC - PubMed
Perloff 2011
    1. Perloff MD, Thaler DE, Otis JA. Anorgasmia with gabapentin may be common in older patients. American Journal of Geriatric Pharmacotherapy 2011;9(3):199‐203. [DOI: 10.1016/j.amjopharm.2011.04.007] - DOI - PubMed
Phillips 2010
    1. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV‐associated sensory neuropathy: a systematic review and meta‐analysis of randomised controlled trials. PLoS One 2010;5(12):e14433. [DOI: 10.1371/journal.pone.0014433] - DOI - PMC - PubMed
Rall 1992
    1. Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Goodman LS, Gilman A, Rall TW, Nies AS, Taylor P editor(s). The Pharmacological Basis of Therapeutics. 8th Edition. Toronto: McGraw‐Hill, 1992:436‐62.
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56:127‐38. [DOI: 10.1016/0304-3959(94)90086-8] - DOI - PubMed
Semel 2010
    1. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Family Practice 2010;11:85. [DOI: 10.1186/1471-2296-11-85] - DOI - PMC - PubMed
Shea 2007
    1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10] - DOI - PMC - PubMed
Smalldone 2004
    1. Smaldone M, Sukkarieh T, Reda A, Khan A. Epilepsy and erectile dysfunction: a review. Seizure 2004;13(7):453‐9. [DOI: 10.1016/j.seizure.2003.12.006] - DOI - PubMed
Sommer 2012
    1. Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, et al. Drug therapy of fibromyalgia syndrome. Systematic review, meta‐analysis and guideline [Medikamentöse Therapie des Fibromyalgiesyndroms]. Der Schmerz 2012;26(3):297‐310. [DOI: 10.1007/s00482-012-1172-2] - DOI - PubMed
Song 2003
    1. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ 2003;326(7387):472. [DOI: 10.1136/bmj.326.7387.472] - DOI - PMC - PubMed
Soni 2013
    1. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community‐based study. Arthritis and Rheumatism 2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962] - DOI - PMC - PubMed
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365-2125.2008.03200.x.] - DOI - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia – responder analysis from individual patient data. BMC MUsculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurololgy 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Sweetman 2005
    1. Sweetman S (editor). Martindale: The Complete Drug Reference. 4th Edition. London: Pharmaceutical Press, 2005:353‐358. [ISBN: 0 85369 550 4]
Thornton 2000
    1. Thornton A, Lee P. Publication bias in meta‐analysis: its causes and consequences. Journal of Clinical Epidemiology 2000;53(2):207‐16. [DOI: 10.1016/S0895-4356(99)00161-4] - DOI - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] - DOI - PubMed
Toth 2005
    1. Toth M. The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate. Medical Hypotheses 2005;64(2):267‐72. [DOI: 10.1016/j.mehy.2004.07.019] - DOI - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. - PubMed
Wolfe 1990
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33:160‐72. - PubMed
Wolfe 2010
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62:600‐10. [DOI: 10.1002/acr.20140] - DOI - PubMed
Woolf 1999
    1. Woolf CJ, Mannion R. Neuropathic pain, aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959‐64. - PubMed
Zaccara 2011
    1. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta‐analysis of randomized controlled trials. Epilepsia 2011;52(4):826‐36. [DOI: 10.1111/j.1528-1167.2010.02966.x] - DOI - PubMed
Zheng 2010
    1. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Valles AS, et al. The anticonvulsive drug lamotrigine blocks neuronal{alpha}4{beta}2‐nicotinic acetylcholine receptors. The Journal of Pharmacology and Experimental Therapeutics 2010;335(2):401‐8. [DOI: 10.1124/jpet.110.171108] - DOI - PubMed
Üçeyler 2013
    1. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel‐Schneider S, Schmid A, et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136(6):1857‐67. [DOI: 10.1093/brain/awt053] - DOI - PubMed

References to other published versions of this review

Wiffen 2000
    1. Wiffen P, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001133] - DOI - PubMed
Wiffen 2005
    1. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. 19.Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD001133.pub2] - DOI - PubMed
Wiffen 2010
    1. Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3] - DOI - PMC - PubMed

Publication types